Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute essential components of the TME.
Voluntarily withdrawn indications included: nivolumab (Opdivo) as a treatment for patients with small cell lung cancer (SCLC) whose disease has progressed after platinumbased chemotherapy and at least 1 other line of therapy, which Bristol Myers Squibb announced in December 2020;2 durvalumab (I...
“[Investigators are] also looking at a carboplatin-paclitaxel backbone with durvalumab (Imfinzi) followed by durvalumab maintenance plus or minus olaparib [after first-line treatment of advanced or recurrent endometrial cancer],” O’Malley said. DUO-E is a randomized, double-blind, placebo-controll...
p < 0.05). A similar cytotoxic effect of verteporfin plus chemoimmunotherapy (verteporfin plus atezolizumab, etoposide and cisplatin) was found in H2286 cells, another SCLC-Y cell line. In these two SCLC-Y cell lines, dramatically increased proportions...
Patients were eligible if they had: (i) biopsy-proven SCLC, (ii) stage IV disease, or (iii) treatment with platinum-etoposide chemotherapy alone (CT group) or in association with first-line PD-L1 inhibitors, atezolizumab, or durvalumab (CIT group). Patients were excluded if: (i) the dela...
Similar results were obtained in the MEDIOLA trial, a phase I/II basket study investigating niraparib plus durvalumab in patients with germline BRCA mutation [42]. Several other clinical trials, aimed at evaluating the safety and efficacy of PARP inhibitors in combination with immune checkpoint ...
Phase II study assessingtolerability, efficacy, and biomarkers for durvalumab ± tremelimumab andgemcitabine/cisplatin in chemo-naïve advanced biliary tract cancer 关于慧渡医疗 慧渡医疗是一家专注于精准医疗的高科技集团公司。我们致力于研究肿瘤分子机制,开发用于癌症诊断和用药监测的基因检测方法及生物信息学算法...
In doing so, we used a structure-based virtual assessment way of medicine repurposing that included high-throughput docking of this C171Q KasA enzyme with substances through the collection of bioactive particles including the FDA-approved drugs and investigational drug applicants, evaluation of this bi...
Safety and efficacy of durvalumab with R-CHOP or R-2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP)... GS Nowakowski...
The introduction of neoadjuvant chemoimmunotherapy has transformed the treatment landscape for early TNBC. However, several challenges, including patient selection, toxicity management, and the identification of predictive biomarkers, need to be addressed. Future research should focus on refining the timing ...